Michael Pedersen
Papers
1
Total Citations
4
H-Index
1
About
Michael Pedersen is a leading urologic oncologist whose research focuses on optimizing treatment outcomes for renal cell carcinoma (RCC), with particular expertise in comparing surgical and ablative techniques. His major contributions center on renal function preservation in patients with clinical T1 RCC, where he has conducted prospective studies evaluating the comparative effectiveness of robot-assisted partial nephrectomy (RAPN) and percutaneous cryoablation (PCA). His landmark 2023 prospective study, which has already garnered significant attention with 4 citations, systematically investigated how baseline renal function influences post-procedural outcomes, providing crucial evidence for treatment selection in kidney cancer patients. This work has helped establish more nuanced guidelines for choosing between nephron-sparing surgery and thermal ablation, directly impacting clinical decision-making for thousands of patients annually. Pedersen’s research is distinguished by its rigorous prospective methodology in a field dominated by retrospective analyses, and his findings have been instrumental in demonstrating that both RAPN and PCA offer excellent renal functional preservation, though the optimal approach depends on individual patient characteristics. His ongoing work continues to shape the standard of care in minimally invasive kidney cancer treatment.
Research Focus
Key Achievements
Top Papers
- 1